Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Rang in aandelen #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Aandeelprijs
$19.30
Laatst gesynchroniseerd: 2023-12-26
Marktkapitalisatie
$72.77M
Verandering (1 dag)
6.22%
Verandering (1 jaar)
0.00%
Land
US
Handel Aeglea BioTherapeutics, Inc. (AGLE)

Categorie

Koersgeschiedenis voor Aeglea BioTherapeutics, Inc. (AGLE)
Hoogste slotkoers: $17.81 op 2023-12-01

Laagste slotkoers: $240.00 op 2016-04-01
Koersgeschiedenis van Aeglea BioTherapeutics, Inc. van 2016 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH